Skip to main content

Table 4 Any Grade of Treatment-Related Adverse Events (TRAEs)

From: Real-world effectiveness of second-line Afatinib versus chemotherapy for the treatment of advanced lung squamous cell carcinoma in immunotherapy-naïve patients

  Afatinib
(n = 19)
Chemotherapy
(n = 89)
p-value
TRAEs 17 (89.5) 65 (73.0) 0.128
Skin toxicity (paronychia, rash, acne), n (%) 17 (89.5) 5 (5.6) < 0.001
Gastrointestinal toxicity (nausea, vomiting, diarrhea), n (%) 17 (89.5) 10 (11.2) < 0.001
Mucositis, n (%) 4 (21.1) 10 (11.2) 0.248
Abnormal liver function, n (%) 0 (0) 7 (7.9) 0.206
Hematologic toxicity (neutropenia, anemia, thrombocytopenia), n (%) 1 (5.3) 61 (68.5) < 0.001
Neuropathy, n (%) 0 (0) 15 (16.9) 0.156